
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 2, Issue 8 1373-1381, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
Y Hattori, H Itoh, S Uchino, K Hosokawa, A Ochiai, Y Ino, H Ishii, H Sakamoto, N Yamaguchi, K Yanagihara, S Hirohashi, T Sugimura and M Terada
Divisions of Genetics, Pathology, and Cancer Information and Epidemiology, National Cancer Center Research Institute, Tokyo 104, Japan.
The K-sam gene, originally isolated as an amplified gene from the stomach cancer cell line KATO-III, is characterized by its preferential amplification in the undifferentiated type (diffuse type) of stomach cancer and encodes one of the receptors for heparin-binding growth factors or fibroblast growth factors. The K-sam gene has been isolated by different methods and has been designated BEK, TK14, and Cek2. The receptor for keratinocyte growth factor was also found to be encoded by the same gene. To examine the expression of the K-sam protein in stomach cancer, polyclonal antibody pK1-2 was raised against the extracellular domain of the gene product. This antibody detected K-sam proteins by Western blot and flow cytometry analyses in stomach cancer cell lines KATO-III and HSC39, in which the K-sam gene is amplified and overexpressed. By immunohistochemical analysis, 20 of 38 cases of the undifferentiated type of advanced stomach cancer were K-sam positive, whereas none of 11 cases of the differentiated or intestinal type revealed K-sam staining. The K-sam product was observed predominantly in diffusely infiltrative lesions. In one autopsy case, the K-sam protein was detected only focally in the primary tumor, whereas markedly increased staining for the K-sam product was detected diffusely in the metastasized tumor in the lymph node and liver. These results suggest that K-sam overexpression is associated with the malignant phenotype of the undifferentiated type of stomach cancer, such as infiltrative growth and metastasis.
This article has been cited by other articles:
![]() |
T. Kondo, L. Zheng, W. Liu, J. Kurebayashi, S. L. Asa, and S. Ezzat Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression Cancer Res., June 1, 2007; 67(11): 5461 - 5470. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takeda, T. Arao, H. Yokote, T. Komatsu, K. Yanagihara, H. Sasaki, Y. Yamada, T. Tamura, K. Fukuoka, H. Kimura, et al. AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor Clin. Cancer Res., May 15, 2007; 13(10): 3051 - 3057. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Finch and J. S. Rubin Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst, June 21, 2006; 98(12): 812 - 824. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Baird, S. Davis, C. R. Antonescu, U. L. Harper, R. L. Walker, Y. Chen, A. A. Glatfelter, P. H. Duray, and P. S. Meltzer Gene Expression Profiling of Human Sarcomas: Insights into Sarcoma Biology Cancer Res., October 15, 2005; 65(20): 9226 - 9235. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakazawa, M. Yashiro, and K. Hirakawa Keratinocyte Growth Factor Produced by Gastric Fibroblasts Specifically Stimulates Proliferation of Cancer Cells from Scirrhous Gastric Carcinoma Cancer Res., December 15, 2003; 63(24): 8848 - 8852. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Jang, K.-H. Shin, and J.-G. Park Mutations in Fibroblast Growth Factor Receptor 2 and Fibroblast Growth Factor Receptor 3 Genes Associated with Human Gastric and Colorectal Cancers Cancer Res., May 1, 2001; 61(9): 3541 - 3543. [Abstract] [Full Text] |
||||
![]() |
A. K. Walch, H. F. Zitzelsberger, J. Bruch, G. Keller, D. Angermeier, M. M. Aubele, J. Mueller, H. Stein, H. Braselmann, J. R. Siewert, et al. Chromosomal Imbalances in Barrett’s Adenocarcinoma and the Metaplasia-Dysplasia-Carcinoma Sequence Am. J. Pathol., February 1, 2000; 156(2): 555 - 566. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ueda, H. Sasaki, Y. Kuwahara, M. Nezu, T. Shibuya, H. Sakamoto, H. Ishii, K. Yanagihara, K.-i. Mafune, M. Makuuchi, et al. Deletion of the Carboxyl-Terminal Exons of K-sam/FGFR2 by Short Homology-mediated Recombination, Generating Preferential Expression ofSpecific Messenger RNAs Cancer Res., December 1, 1999; 59(24): 6080 - 6086. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |